Table 3.

Odds ratios (ORs) for severe COVID-19 obtained from logistic regression models adjusted for age and pancreatic insufficiency in patients with cystic fibrosis infected by SARS-CoV-2 between March 2020 and June 2021 in Italy, according to selected clinical characteristics

	OR [95% CI]	P*
FEV1p (< 40% vs ≥ 40%)	4.54 [1.56–13.19]	0.005
Oxygen (Yes vs No)	12.27 [2.91–51.68]	< 0.001
Chronic Pa infection (Yes vs No)	1.77 [0.84–3.73]	0.135
Underweight (Yes vs No)	2.92 [1.12–7.57]	0.028
Organ transplant (Yes vs No)	7.31 [2.59–20.65]	< 0.001
Diabetes (Yes vs No)	2.67 [1.23–5.80]	0.013
Liver disease (Yes vs No)	3.67 [1.77–7.59]	< 0.001
CFTR modulators (HE vs None)	0.42 [0.09–2.02]	0.501
CFTR modulators (OM vs None)	0.97 [0.39–2.41]
Inhaled steroids (Yes vs No)	1.20 [0.59–2.43]	0.621
Dornase alfa (Yes vs No)	0.34 [0.13–0.88]	0.026
Azithromycin (Yes vs No)	2.58 [1.27–5.25]	0.009

HE highly effective modulators, OM Other CFTR modulators

*P values were obtained using the likelihood ratio test between two nested models (i.e., the null model and the model including the variable of interest)